The Trump administration is expanding its data push, reaching into domains long controlled by the states — and further into ...

Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural phenomenon.

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach ...

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

Why Republicans think that insurance should be tied to employment — and that it’s not essential to have at all.

The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.

Shares of Eli Lilly And Co. (LLY) and Novo Nordisk (NVO) jumped on Friday following reports that the Trump administration is ...

The Trump administration is considering a five-year pilot program to cover weight-loss drugs under Medicare and Medicaid, the ...

Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The ...

Medicare and Medicaid move toward covering Ozempic and other weight loss drugs - The proposed plan could go into effect as early as next April for those on Medicaid ...